Prolonged Third Remission in a Patient With Acute Promyelocytic Leukemia After Consolidation Chemotherapy With Intermittent Intermediate Dose Ara-C and Maintenance With Intermittent all-trans Retinoic Acid (ATRA)

References

• Castaigne S., Chomienne C, Daniel M. T., Ballerini P., Berger R., Fenaux P., Degos L. All-trans retin-oic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Laczika K., Mitterbauer G., Korninger L., Knoebl P., Schwarzinger I., Kapiotis S., Haas O. A., Kyrle P. A., Pont J., Oehler L., Burtscher B., Thalhammer R, Lechner K., Jaeger U. Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)-negativity by combined treatment with all-frans-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study. Leukemia 1994; 8: 1–5
   PubMed Web of Science ®Google Scholar
• Fenaux P., Degos L. Treatment of acute promyelocytic leukaemia. Baillieres Clinical Haematology 1996; 9: 107–228
   PubMed Web of Science ®Google Scholar
• Fenaux P., Chastang M., Sanz M., Thomas H., Dombret H., Link H., Guerci A., Fegueux N., San Miguel J., Rayon C, Ziltoun R., Gardin C, Maloise) F., Fey M, Travade P., Reiffers J., Stamatoulas A., Stoppa A. M., Caillot D., Lefrère F., Hayat M., Castaigne S., Chomienne C, Degos L. ATRA followed by chemotherapy vs. ATRA plus CT and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia (APL): results of APL 93 trial. Annals of Hematology 1998; 92(Suppl II)14, and the European APL Group;, A-56
   Google Scholar
• Lo Coco F., Nervi C, Avvisati G., Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia 1998; 12: 1866–1880
   PubMed Web of Science ®Google Scholar
• Mandelli F., Diverio D., Avvisati G., Luciano A., Barbui T., Bernasconi C, Broccia C, Cerri R., Falda M., Fiori-toni G., Leoni F., Liso V., Petti M. C., Rodeghiero F., Saglio G., Vegna M. L., Visani G., Jehn U., Willemze R., Muus P., Pelicci P. G., Biondi A., Lo Coco F. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014–1021, for the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pedi-atrica Cooperative Groups
   PubMed Web of Science ®Google Scholar
• Tallmann M. S., Andersen J., Schiffer C. A., Appelbaum F. R., Feusner J. E., Ogden A., Shepherd L., Wilman C., Bloomfield CD., Rowe J. M., Wiernik P. H. All-trans retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine 1997; 337: 1021–1028
   PubMed Web of Science ®Google Scholar
• Delva L., Comic M., Balitrand N., Guidez F., Micléa J. M., Delmer A., Teiller F., Fenaux P., Castaigne S., Degos L., Chomienne C. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1992; 82: 2175–2181
   Web of Science ®Google Scholar
• Muindi J., FrankeJ S. R., Miller W. H., Jr, Jakubowski A., Scheinberg D. A., Young C, Dmitrivsky E., Warrell R. P., Jr. Continuous tretment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoic “resistance” in patients with acute promyelocytic leukemia. Blood 1992; 79: 299–303
   PubMed Web of Science ®Google Scholar
• Frankel S. R., Eardley A., Lauwers G., Weiss M., Warrell R. P., Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Annals of Internal Medicine 1992; 117: 292–296
   PubMed Web of Science ®Google Scholar
• De Botton S., Dombret H., Sanz M., San Miguel J., Caillot D., Zittoun R., Gardembras M., Stamatoulas A., Condé E., Guerci A., Gardin C, Geiser K., Cony Makhoul D., Reman O., de la Serna J., Lefrere F., Chomienne C, Chastang C, Degos L., Fenaux P. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1993; 92: 2712–2718, the European APL Group
   Google Scholar
• Shen Z. X., Chen G. Q., Ni J. H., Li X. S., Xiong S. M., Qiu Q. Y., Zhu J., Tang W., Sun G. L., Yang K. Q., Chen Y, Zhou L., Fang Z. W., Wang Y. T., Ma J., Zhang P., Zhang T. D., Chen S. J., Chen Z., Wang Z. L. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II: Clinical efficacy and pharmacoki-netics in relapsed patients. Blood 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Soignee S. L., Masiak P., Wang Z. G., Jhanwar S., Calleja E., Dardashti L. J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D. A., Pandolfi P. P., Warrell R. P., Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine 1998; 119: 1341–1348
   Web of Science ®Google Scholar
• Estey E., Thall P. E., Pierce S., Kantarijian H., Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. Journal of Clinical Oncology 1997; 15: 483–490
   PubMed Web of Science ®Google Scholar
• Hofmann R., Haddad N., Sahar D., Rosenbaum H., Brenner B., Rowe M. High dose cytarabine induces a molecular remission in APL patients who failed to achieve a complete response following treatment with ATRA and anthracycliness. Blood 1998; 92(Suppl 1)A-2517–610a
   Google Scholar
• Sung K. W., Choi H.S., Yoo E.S., Rhu K. H., Shin H. Y., Ahn H. S. Clinical trial of low dose cylosine arabino-side in the treatment of acute promyelocytic leukemia. Journal of Korean Medical Science 1997; 12: 298–304
   PubMedGoogle Scholar
• Sperr W. R., Piribauer M., Agis H., Mitterbauer M., Gei-ssler K., Haas O., Fonatsch C, Jager U., Schwarzinger I., Thalhammer F, Valent P., Lechner K. Intermittent intermediate dose ARA-C as consolidation therapy for AML in the elderly. Blood 1997; 90(Suppl 1)509
   Google Scholar
• EORTC-06952. Phase 111 randomized study of maintenance therapy with MP/MTX vs TRA vs MP/MTX alternating with TRA vs no further therapy following induction with TRA/IDA and intensive consolidation with ARA-C/1DA, DHAD/VP-16, and IDA/ARA-C/TG with or without BMT in acute promyelocytic leukemia
   Google Scholar
• Korninger L., Knöbl P., Laczika K., Mustafa S., Quehen-berger P., Schwarzinger I., Lechner K., Jaeger U., Mannhalter C. PML-RARa PCR positivity in the bone marrow of patients with APL precedes huematological relapse by 2 - 3 months. British Journal of Haematology 1994; 88: 427–431
   PubMed Web of Science ®Google Scholar
• Ghaddar H. M., Plunkett W., Kantarijan H. M., Pierce S., Freireich E. J., Keating M. J., Estey E. H. Long-term results following treatment of newly diagnosed acute myelogenuous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 1994; 8: 1269–1274
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Yano T., Omoto E., Takahashi K., Kibata M., Shudo K., Ueda R., Ohno R., Harada M. Re-induction of complete remission with a new synthetic ret-inoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid. British Journal of Haematology 1997; 97: 137–140
   PubMed Web of Science ®Google Scholar